Pioglitazone in the treatment of NASH: the role of adiponectin.
about
Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directionsNonalcoholic steatohepatitis: emerging targeted therapies to optimize treatment optionsPathophysiology of Non Alcoholic Fatty Liver DiseaseBiomarkers in nonalcoholic fatty liver diseaseInflammation in nonalcoholic steatohepatitis.Obesity as the common soil of non-alcoholic fatty liver disease and diabetes: Role of adipokines.Fatty liver index predicts further metabolic deteriorations in women with previous gestational diabetesFibrogenesis and Carcinogenesis in Nonalcoholic Steatohepatitis (NASH): Involvement of Matrix Metalloproteinases (MMPs) and Tissue Inhibitors of Metalloproteinase (TIMPs).Nonalcoholic Fatty liver disease: pathogenesis and therapeutics from a mitochondria-centric perspective.Correction of liver steatosis by a hydrophobic iminosugar modulating glycosphingolipids metabolism.Non alcoholic steatohepatitis a precursor for hepatocellular carcinoma development.Genetic determinants of hepatic steatosis in man.Adiponectin, a key adipokine in obesity related liver diseasesRegulation of glucose and lipid homeostasis by adiponectin: effects on hepatocytes, pancreatic β cells and adipocytesComparison of the efficacy of cardamom (Elettaria cardamomum) with pioglitazone on dexamethasone-induced hepatic steatosis, dyslipidemia, and hyperglycemia in albino rats.An Endocrine Perspective of Nonalcoholic Fatty Liver Disease (NAFLD).Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis.Adiponectin as an anti-fibrotic and anti-inflammatory adipokine in the liver.The association between hepatic fat content and liver injury in obese children and adolescents: effects of ethnicity, insulin resistance, and common gene variantsNon-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart diseaseVitamin D and nonalcoholic fatty liver disease (NAFLD): is it more than just an association?Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease.Revisiting weight reduction and management in the diabetic patient: Novel therapies provide new strategies.Effect of pioglitazone, quercetin and hydroxy citric acid on extracellular matrix components in experimentally induced non-alcoholic steatohepatitis.Liver fibrogenesis in non-alcoholic steatohepatitis.Non-alcoholic steatohepatitis: the therapeutic challenge of a global epidemic.Therapeutic effects of globular adiponectin in diabetic rats with nonalcoholic fatty liver disease.Chronic hepatitis C genotype 1 patients with insulin resistance treated with pioglitazone and peginterferon alpha-2a plus ribavirin.Hepatic fat loss in advanced nonalcoholic steatohepatitis: are alterations in serum adiponectin the cause?Practical strategies for improving outcomes in T2DM: The potential role of pioglitazone and DPP4 inhibitors.Concentration-dependent response to pioglitazone in nonalcoholic steatohepatitis.Role of ethnicity in overweight and obese patients with nonalcoholic steatohepatitis.
P2860
Q26751258-9A63FF77-2E5A-4EE7-98BC-253CF1E7CDA7Q26796448-BE90ED43-34C3-49F3-881F-A8AD17EED4C7Q28070011-13CD9E24-2B1C-4A82-AB68-453CED7440A2Q28080541-2296FF51-7365-4878-95E1-91F43F8F1BCEQ30453231-082161C8-82F2-442F-AA6E-90CA67F7BCBCQ33628222-1F71D9C4-2BAF-472B-B6AC-5D2E56FF858AQ34185998-7A2FB290-E987-4E95-A21E-88ACE2EB6739Q34309876-EE94DC95-3BEE-4853-8BE9-BF7A34FFCAD6Q34412650-F15890F4-7D72-4E88-BCEC-116992A420EAQ34440771-8294EA54-19E3-4A2A-9E68-BAA2DE6F9019Q34589677-8DA859E5-D21F-4809-A963-76FE6F5C42ABQ34646183-B7EF4C29-1854-47C4-911C-D100388E8F0EQ35061908-3FE457CF-60FA-4B4B-820F-66BB9DB21CA0Q35683960-EC94E733-7A99-428D-963D-0EC5EDB44A08Q35973730-1AE25C73-05B2-4A72-829C-B1D6F59FBD41Q36328050-EAB48809-701D-409B-AB8A-E9D67C6A38A6Q36465496-AE42DFED-91AA-4034-A824-5DD453C887E0Q36551969-0B78FC87-E502-45C1-88FA-73EB7D84C5FDQ36782785-8B876C1C-2DFE-4898-87AE-F76BB2634D47Q37002532-0477B11F-8A05-451C-AC85-2AE5FC4742ADQ38090585-584B0A30-C0C9-44D3-87D4-8C4040059ADBQ38199526-23416474-6416-40C5-B12D-5359B7224FF7Q38442816-7B99F247-BBB4-42F2-B11F-C19A4DD0E584Q42022517-387CBFB2-C3DE-49AC-BFBA-24A504650789Q42321514-0F8A8C2E-77F8-42B5-A310-83DF1C42A6A7Q42406740-7978CC31-0811-4DE7-AA92-3CC28761989DQ42961701-D4D3DDF1-585E-4FE4-AE32-594ACCAF44D3Q42977737-4F4DC3DE-065B-47C0-9592-7D6C10061722Q43671252-CD384F2D-A340-4FC7-87F7-80D3692D5B96Q47697775-5B3A145C-10EC-4FDF-9A7E-DC41A5C4684FQ48193707-4F4C0956-634B-40F9-AA24-AEF79DE430A2Q51372025-FB816D77-0AD3-4C5D-9EAD-52BD2D347A12
P2860
Pioglitazone in the treatment of NASH: the role of adiponectin.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Pioglitazone in the treatment of NASH: the role of adiponectin.
@en
Pioglitazone in the treatment of NASH: the role of adiponectin.
@nl
type
label
Pioglitazone in the treatment of NASH: the role of adiponectin.
@en
Pioglitazone in the treatment of NASH: the role of adiponectin.
@nl
prefLabel
Pioglitazone in the treatment of NASH: the role of adiponectin.
@en
Pioglitazone in the treatment of NASH: the role of adiponectin.
@nl
P2093
P2860
P1476
Pioglitazone in the treatment of NASH: the role of adiponectin.
@en
P2093
P2860
P304
P356
10.1111/J.1365-2036.2010.04405.X
P407
P577
2010-09-01T00:00:00Z